Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

6.125 -0.025 (-0.41%)
Streaming Delayed Price Updated: 11:40 AM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Iovance Biotherapeutics Inc

Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission to U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
BLA Submission Ongoing with U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
From Iovance Biotherapeutics, Inc.
Via Globe NewsWire
The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.